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was 2.1  1.6. Both NOAC and Watchman device were superior to
warfarin in hemorrhagic stroke prevention (OR¼0.46 [0.30-0.82] and
OR¼0.21 [0.05-0.99], respectively). NOAC also signiﬁcantly reduced
total stroke compared with warfarin (OR¼0.78 [0.58-0.96]) and
bleeding events (OR¼0.78 [0.65-0.91]). Indirect comparison between
NOAC and Watchman revealed no signiﬁcant differences in outcomes,
though there was a trend toward greater ischemic stroke with
Watchman compared with NOAC (OR 2.60 [0.60-13.96]) (Figure).
CONCLUSIONS NOAC therapy was superior to warfarin for multiple
outcomes while Watchman reduced hemorrhagic stroke. Further
studies are needed to assessWatchman for ischemic stroke prevention.
CATEGORIES ENDOVASCULAR: Stroke and Stroke Prevention
KEYWORDS Anticoagulants, oral, Atrial ﬁbrillation, Watchman
TCT-760
A Meta-Analysis of Embolic Protection Devices in the Prevention of
Cerebrovascular Events after Transcatheter Aortic Valve Replacement
Mohammad M. Ansari,1 Rhanderson N. Cardoso,2 Daniel C. Garcia,3
Marco Spaziano,4 Eduardo de Marchena,5 Derek Brinster,6
S Jacob Scheinerman,7 Giuseppe Martucci,8 Nicolo Piazza9
1University of Miami- Jackson Memorial Hospital, New York, NY;
2University of Miami/Jackson Memorial Hospital, Miami, FL;
3University of Miami/Jackson Memorial Hospital, Miami, FL; 4McGill
University Health Centre, Montreal, Quebec; 5University of Miami
Miller School of Medicine, Miami, FL; 6Lenox Hill Heart and Vascular
Institute, New York, NY; 7Hofstra North-Shore LIJ School of Medicine,
New Hyde Park, NY; 8McGill University Health Center, Royal Victoria
Hospital, Montreal, Quebec; 9McGill University Health Center, Royal
Victoria Hospital, Montreal, Canada
BACKGROUND Cerebrovascular events can occur in up to 7% of pa-
tients following transcatheter aortic valve replacement (TAVR),
increasing dementia and mortality. Neuro-embolic events on post-
TAVR diffusion-weighted (DW) MRI are nearly universal, and have
been associated with cognitive decline. Embolic protection devices
(EPD) have not shown clinical reduction in post-TAVR neuro-embolic
events, but previous studies may have been under-powered to detect
signiﬁcant differences in outcomes.
METHODS We aimed to perform a meta-analysis evaluating EPD in
the prevention of clinical and imaging neuro-embolic events
following TAVR. Databases and conference abstracts were searched
for studies that compared efﬁcacy and safety outcomes of TAVR withand without EPD. Random-effects model was used. Heterogeneity
was examined with Cochran Q test and I2 statistics.
RESULTS A total of 4 studies with 289 patients were included, of
whom 152 (52.5%) underwent TAVR with an EPD. The success rate of
EPD implantation ranged from 89% to 100% (Table 1). In a follow-up
up to 30 days, the use of EPD in TAVR was associated with a
decreased incidence of new neurologic impairment identiﬁed by
specialist application of the National Institute of Health Stroke Scale
(OR 0.40; p¼0.04; Figure 1). EPDs were found to signiﬁcantly
increase ﬂuoroscopy time by a mean of 5.23 minutes (p<0.01). There
were no differences between groups in clinical strokes (p¼0.99),
disabling strokes (p¼0.70), DW-MRI lesions (p¼0.37), major vascular
complications (p¼0.85), life-threatening bleeding (p¼0.81), renal
insufﬁciency (p¼0.44), or mortality (p¼0.66).DesignTotal
population /
Embolic
protection Mean age Male DeviceValves,
number of
patientsProcedural
successCLEAN-TAVI
2014RCT 100 / 50 79 y 43% Claret
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cohort52 / 15 84 y 53% Embrella
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DeﬂectorSAPIEN, 33
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1993%CONCLUSIONS This meta-analysis suggests that EPDs increase ﬂuo-
roscopy time in TAVR, but are otherwise safe, with a high technical
success rate. In addition, these devices have the potential to reduce
the incidence of TAVR-related new neurologic impairment. Thus, a
beneﬁt in the incidence of peri-procedural strokes may become
evident in larger clinical trials. Further studies are warranted to
conﬁrm these ﬁndings.
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BACKGROUND Intravenous thrombolytic therapy is the only FDA
approved treatment for large vessel anterior circulation acute
ischemic stroke (AIS). Previous evidence from randomized trials
evaluating the beneﬁt of endovascular therapy (EVT) for AIS have
shown conﬂicting results. The purpose of this meta-analysis was to
systematically examine clinical outcomes in randomized controlled
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intravenous (IV) thrombolytics, for the treatment of AIS.
METHODS PubMed, Cochrane CENTRAL, EMBASE, EBSCO, Web of
Science and CINAHL databases were searched from 1/01/1995-06/10/
2015. We selected English language RCTs, comparing EVT plus IV tPA
with IV tPA alone in eligible patients for treatment of AIS. Clinical
endpoints of interest were good functional outcomes as represented
by modiﬁed Rankin Scale (mRS) of 0-2, all-cause mortality, and
symptomatic intracerebral hemorrhage (sICH).
RESULTS Ten randomized trials were included in our meta-analysis,
which randomized 2,915 patients with large vessel, anterior circula-
tion stroke. EVT signiﬁcantly improved the rate of functional inde-
pendence (90-day mRS of 0 to 2) when compared to IV thrombolytics
[Odds ratio (OR) 1.65, 95% CI 1.21-2.26]. There was a non-signiﬁcant
trend of lower mortality with EVT (OR 0.84, 95% CI 0.69-1.03). The
rate of sICH was not higher with EVT (OR 1.06, 95% CI 0.74-1.52).
CONCLUSIONS In recent trials with modern imaging and thrombec-
tomy devices in patients with AIS, EVT signiﬁcantly improved func-
tional outcomes and was as safe as conventional intravenous
thrombolytic therapy.
CATEGORIES ENDOVASCULAR: Stroke and Stroke Prevention
KEYWORDS Endovascular therapy, Stroke
TCT-762
Smartphone Based Applications Accurately Predict Rhythm Disturbances
and Diagnose Silent Atrial Fibrillation
Onkar Sandhu,1 Bipin Joshi1
1University of San Francisco at Fresno, Clovis, CA
BACKGROUND Use of smartphone-based applications for identifying
rhythm disturbances has been suggested. However their practical use
and appropriate utilization to screen for rhythm disorders in outpa-
tient settings remains undeﬁned.
METHODS I evaluated 103 consecutive patients in outpatient cardi-
ology clinics to identify underlying heart rhythm using smartphone-
based electrocardiogram (ECG) application, subsequently validated by
12-lead ECG. Two cardiologists blinded to the rhythm diagnosis
independently read both ECG tracings.
RESULTS Mean age was 6215 years, 49 (47.6%) patients were males
and 89% patients were Caucasians. Identiﬁcation of underlying heart
rhythm by smartphone-based application is shown in Figure 1-A,
which accurately identiﬁed sinus rhythm from Atrial Fibrillation
(AF) with sensitivity of 88%, speciﬁcity of 91% and positive
predictive value of 98%. Comparison of rhythm by smartphone
based application and 12-lead ECG showed an Intraclass correlation
coefﬁcient of 0.838 (95% Conﬁdence Interval: 0.7860-
0.890;p<0.001). Receiver operating characteristic curve for
smartphone-based application to diagnose AF showed area under
curve of 0.881.Superiority of Alivecor For Identifying Sinus Rhythm and Atrial FibrillationRhythm Analysis
by AlivecorAtrial Fibrillation
(n[8)Sinus rhythm
(n[92)Sensitivity 0.62 0.88Speciﬁcity 0.98 0.91Positive Predictive Value 0.83 0.98Negative Predictive Value 0.96 0.47Positive Likely hood ratios 59.37 9.68Negative Likely hood ratios 0.37 0.13CONCLUSIONS Smartphone-based ECG applications can accurately
determine rhythm disturbances and diagnose silent AF in outpatient
settings. In an era of evolving smartphones, such ECG applications may
be of value in risk assessment, guiding therapy and preventing strokes.
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BACKGROUND Clopidogrel plays a central role in the treatment of
patients undergoing carotid artery stenting (CAS). The inhibitory
response to clopidogrel considerably varies among individuals and
clopidogrel resistance is a risk factor for thrombotic events. Based on
the platelet aggregation evaluated by the VASP analysis, the present
study compared the outcome after carotid stenting guided with
optimal clopidogrel dose adjustment versus a groups treated with
double dose of clopidogrel without platelet monitoring.
METHODS From January 2002 until January 2014, 176 consecutive
patients underwent an elective carotid stenting. The ﬁrst group was
treated with clopidogrel, guided with VASP analysis and was compared
with a control groups treated with double dose of clopidogrel without
platelet monitoring. VASP phosphorylation was determined with
Platelet VASP kits according to the manufacturer’s instructions (Diag-
nostica Stago, Asnières, France). A ﬁrst VASP-phosphorylation analysis
was checked and considered safe if the platelet reactivity indexwas less
than 55%. If not, additional 75 mg loading dose was control checked by
another VASP-phosphorylation analysis.
RESULTS The study enrolled 176 patients. Of these, 130 patients were
treated with clopidogrel guided with VASP analysis (group 1), and 46
treated with double dose of clopidogrel without platelet monitoring
(group 2). At baseline, the clinical features and the procedural tech-
nique did not differ between the 2 groups. No additional gain of
mortality, ischemic event, cumulative incidence of target lesions
revascularization (TLR) or bleeding was obtained at 30 days, one-year
and Three –years in Group 1 versus Group 2. VASP monitoring was not
correlated to the occurrence of complications at one month and one-
year follow up (OR (95% CI): 1.06 (0.27 - 4.19) p:0,93) ; OR (95% CI):
1.07(1.39 - 2.92) p: 0,9; respectively) .
CONCLUSIONS Patients undergoing CAS treated with double-dose clo-
pidogrel have the same outcomes compared with a population treated
with clopidogrel guided with VASP analysis. VASP monitoring is not
associated with a lower incidence of death, ischemic event, cumulative
incidence of TLR or bleeding after CAS. Vu : 15:31 Appareil photo
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